top of page

NERV

Minerva Neurosciences

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$54.9 M

Burn Rate (Qtr)

$5.8 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

NERV

BPIQ_Logo_RGB-01.jpg

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options.

Recent Posts

See what the community is saying - click to see full post.

J.P. Morgan Healthcare Conference

September 2021 Big-Mover™ Stocks to Watch and Movers to Watch List

SUPN - Refusal to File (RTF) letter from the FDA regarding its NDA for SPN-830 for the treatment of Parkinson’s disease (PD)

bottom of page